Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs ma...
Published in: | Asian Pacific Journal of Tropical Medicine |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018
|
Subjects: | |
Online Access: | https://doi.org/10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c |
id |
ftdoajarticles:oai:doaj.org/article:59bafae6482248a6996e0775285d149c |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:59bafae6482248a6996e0775285d149c 2023-05-15T15:08:46+02:00 Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy Anbarasu Sivaraj Revathy Sundar Radhakrishnan Manikkam Krupakar Parthasarathy Uma Rani Vanaja Kumar 2018-01-01T00:00:00Z https://doi.org/10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c EN eng Wolters Kluwer Medknow Publications http://www.apjtm.org/article.asp?issn=1995-7645;year=2018;volume=11;issue=8;spage=453;epage=459;aulast=Sivaraj https://doaj.org/toc/2352-4146 2352-4146 doi:10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c Asian Pacific Journal of Tropical Medicine, Vol 11, Iss 8, Pp 453-459 (2018) bacteriocin lactic acid bacteria antimycobacterial peptides tuberculosis immunomodulation hybrid bacteriocin Arctic medicine. Tropical medicine RC955-962 article 2018 ftdoajarticles https://doi.org/10.4103/1995-7645.240080 2022-12-31T02:10:54Z Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs make the treatment options more complicated. Hence, there are necessities to identify new drug candidates to fight against various sub-populations of M. tuberculosis with less or no toxicity/side effects and shorter treatment duration. Bacteriocins produced by lactic acid bacteria (LAB) attract attention of researchers because of its “Generally recognized as safe” status. LAB and its bacteriocins possess an effective antimicrobial activity against various bacteria and fungi. Interestingly bacteriocins such as nisin and lacticin 3147 have shown antimycobacterial activity in vitro. As probiotics, LAB plays a vital role in promoting various health benefits including ability to modulate immune response against various infectious diseases. LAB and its metabolic products activate immune system and thereby limiting the M. tuberculosis pathogenesis. The protein and peptide engineering techniques paved the ways to obtain hybrid bacteriocin derivatives from the known peptide sequence of existing bacteriocin. In this review, we focus on the antimycobacterial property and immunomodulatory role of LAB and its metabolic products. Techniques for large scale synthesis of potential bacteriocin with multifunctional activity and enhanced stability are also discussed. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Asian Pacific Journal of Tropical Medicine 11 8 453 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
bacteriocin lactic acid bacteria antimycobacterial peptides tuberculosis immunomodulation hybrid bacteriocin Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
bacteriocin lactic acid bacteria antimycobacterial peptides tuberculosis immunomodulation hybrid bacteriocin Arctic medicine. Tropical medicine RC955-962 Anbarasu Sivaraj Revathy Sundar Radhakrishnan Manikkam Krupakar Parthasarathy Uma Rani Vanaja Kumar Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
topic_facet |
bacteriocin lactic acid bacteria antimycobacterial peptides tuberculosis immunomodulation hybrid bacteriocin Arctic medicine. Tropical medicine RC955-962 |
description |
Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (M. tuberculosis). WHO estimated that 10.4 million new (incident) TB cases worldwide in year 2016. The increased prevalence of drug resistant strains and side effects associated with the current anti-tubercular drugs make the treatment options more complicated. Hence, there are necessities to identify new drug candidates to fight against various sub-populations of M. tuberculosis with less or no toxicity/side effects and shorter treatment duration. Bacteriocins produced by lactic acid bacteria (LAB) attract attention of researchers because of its “Generally recognized as safe” status. LAB and its bacteriocins possess an effective antimicrobial activity against various bacteria and fungi. Interestingly bacteriocins such as nisin and lacticin 3147 have shown antimycobacterial activity in vitro. As probiotics, LAB plays a vital role in promoting various health benefits including ability to modulate immune response against various infectious diseases. LAB and its metabolic products activate immune system and thereby limiting the M. tuberculosis pathogenesis. The protein and peptide engineering techniques paved the ways to obtain hybrid bacteriocin derivatives from the known peptide sequence of existing bacteriocin. In this review, we focus on the antimycobacterial property and immunomodulatory role of LAB and its metabolic products. Techniques for large scale synthesis of potential bacteriocin with multifunctional activity and enhanced stability are also discussed. |
format |
Article in Journal/Newspaper |
author |
Anbarasu Sivaraj Revathy Sundar Radhakrishnan Manikkam Krupakar Parthasarathy Uma Rani Vanaja Kumar |
author_facet |
Anbarasu Sivaraj Revathy Sundar Radhakrishnan Manikkam Krupakar Parthasarathy Uma Rani Vanaja Kumar |
author_sort |
Anbarasu Sivaraj |
title |
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
title_short |
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
title_full |
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
title_fullStr |
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
title_full_unstemmed |
Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
title_sort |
potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy |
publisher |
Wolters Kluwer Medknow Publications |
publishDate |
2018 |
url |
https://doi.org/10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Asian Pacific Journal of Tropical Medicine, Vol 11, Iss 8, Pp 453-459 (2018) |
op_relation |
http://www.apjtm.org/article.asp?issn=1995-7645;year=2018;volume=11;issue=8;spage=453;epage=459;aulast=Sivaraj https://doaj.org/toc/2352-4146 2352-4146 doi:10.4103/1995-7645.240080 https://doaj.org/article/59bafae6482248a6996e0775285d149c |
op_doi |
https://doi.org/10.4103/1995-7645.240080 |
container_title |
Asian Pacific Journal of Tropical Medicine |
container_volume |
11 |
container_issue |
8 |
container_start_page |
453 |
_version_ |
1766340074164715520 |